Global Opioid Induced Constipation Market Report and Forecast 2024-2032

Global Opioid Induced Constipation Market Outlook

The global opioid induced constipation market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032, driven by the rising prevalence of diseases and the rising cases of accidents.

Opioid Induced Constipation: Introduction

Opioids, sometimes called narcotics, are medications prescribed by doctors to treat persistent or severe pain. They are used by people with chronic headaches and backaches, by patients recovering from surgery or experiencing severe pain associated with cancer, and by adults and children who have gotten hurt playing sports or who have been seriously injured in falls, auto accidents, or other incidents. The central nervous system oversees how the body responds to pain. It also controls involuntary movements, including those of the digestive tract.

Medications which contain substances like morphine, codeine, oxycodone, and methadone are highly capable of causing opioid induced constipation. Common symptoms may include abdominal tenderness, bloating, distention, difficulty defecating, nausea, and vomiting, tiredness and lethargy, and weight loss, among others. Along with the use of medications, some health habits may also help relieve the condition, such as drinking more fluid, consuming more fibre, and getting some exercise.

Global Opioid Induced Constipation Market Analysis

The increasing number of randomized clinical trials to try new and effective treatments for opioid induced constipation are driving the market growth. For example, a randomized trial that took place in China used electroacupuncture for the treatment of opioid induced constipation and found it effective. Results showed improved bowel movement in patients with opioid induced constipation with rare adverse side effects. The increasing research and development for new drugs and therapies to treat chronic diseases, such as cancer, are directly aiding the global opioid induced constipation market share. Key players in the market are also increasing their focus on developing new drugs such as naldemedine and naloxegol, that may help resolve the issue for the patients, some of them being in clinical trials already, further anticipating the market expansion.

Apart from all this, there has been a significant shift towards non-pharmacological solutions to overcome opioid induced constipation. Such as dietary changes, proper hydration, and following an active lifestyle in combination with some regular exercises which may restrict the market growth a bit. The increasing investments by pharmaceutical companies in research and development activities towards producing targeted solutions for opioid induces constipation is also a major trend influencing the opioid induced constipation market growth.

Global Opioid Induced Constipation Market Segmentation

Market Breakup by Product

• Mu-opioid Receptor Antagonists 

• Chloride Channel-2 Activators 

• Others

Market Breakup by Prescription Type

• Over-the-Counter

• Prescription

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Global Opioid Induced Constipation Market Overview

The market for opioid induced constipation has been experiencing a significant boost in the market driven by the increasing prevalence of cancer worldwide. The boost in the market is also driven by the increasing geriatric population globally, which gets more susceptible to several chronic diseases with increasing age such as cancer, chronic backaches, and headaches, among others. The medications that are prescribed by doctors to treat such conditions contain opioid analgesics such as morphine, hydromorphone, and codeine, among others for chronic non-cancer pain with severe adverse effects on the digestive system. The rise in such conditions is the major factor increasing the demand for opioid induced drugs, propelling the market growth. The use of opioid analgesic prescriptions will increase with the growing geriatric population, further escalating the global opioid induced constipation market growth.

North America is expected to dominate the overall opioid-induced constipation market throughout the forecast period. This is due to the rising prevalence of various gastrointestinal disorders among geriatric patients in the region and a steep rise in the consumption of opioids in recent years. Cancer is a major public health problem worldwide and is the second leading cause of death in the United States. In 2024, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States.

Opioid Induced Constipation Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd.

• Mylan N.V.

• Fresenius Kabi AG

• Hikma Pharmaceuticals PLC

• Novartis AG

• Teva Pharmaceutical Industries Ltd.

• Bristol Myers Squibb Company

• GSK Plc.

• Bayer AG

• Aurobindo Pharma

• S.L.A. Pharma AG

• Salix Pharmaceuticals

• Takeda Pharmaceutical Company Limited

Key Highlights of the Report